Sua seleção (0)
Detalhe da pesquisa
1.
The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt.
Blood;
134(Supplement_1): 28, 2019 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31723981
2.
Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.
Blood;
134(Supplement_1): 30, 2019 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724000
3.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet;
394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
4.
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Blood;
2018 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30282798
5.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Clin Cancer Res;
25(22): 6606-6613, 2019 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292142
6.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Br J Haematol;
187(3): 337-346, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271217
7.
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
N Engl J Med;
375(11): 1044-53, 2016 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27626518
8.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood;
129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
9.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer;
124(14): 2956-2963, 2018 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723417
10.
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Ann Hematol;
97(5): 831-837, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29330561
11.
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.
Blood;
125(16): 2486-96; quiz 2586, 2015 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25587040
12.
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
Blood;
125(24): 3711-9, 2015 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25878120
13.
Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Blood;
125(9): 1411-7, 2015 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25575538
14.
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Blood;
121(11): 1968-75, 2013 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23319574
15.
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Haematologica;
100(6): 826-33, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25769541
16.
A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.
Am J Hematol;
90(9): 811-8, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26094614
17.
Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Am J Hematol;
90(11): 986-91, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26214580
18.
A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Am J Hematol;
89(11): 1024-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25052698
19.
Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study.
Blood;
118(19): 5099-107, 2011 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21835957
20.
BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.
Eur J Haematol;
91(6): 552-6, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23927500